Titan Pharmaceuticals Inc represents values of innovation, excellence, and patient-centricity. The company embodies a corporate philosophy focused on developing and commercializing therapeutics for challenging medical conditions. Titan Pharmaceuticals Inc strives to bring transformative solutions to patients by leveraging its expertise in specialty pharmaceuticals. By prioritizing innovation and delivering high-quality products, the company aims to improve patients' lives and enhance healthcare outcomes. With a strong commitment to scientific rigor and regulatory compliance, Titan Pharmaceuticals Inc remains dedicated to fulfilling unmet medical needs and making a positive impact in the healthcare industry.

Titan Pharmaceuticals Inc is primarily present in the United States.

Titan Pharmaceuticals Inc. has achieved several significant milestones. One notable achievement is the approval of Probuphine, a subdermal implant for the maintenance treatment of opioid dependence, by the U.S. Food and Drug Administration (FDA). This groundbreaking product offers an innovative solution for patients undergoing opioid addiction therapy. Additionally, Titan Pharmaceuticals Inc. has established partnerships and collaborations to further enhance its offerings and expand its market reach. The company continues to prioritize research and development, aiming to develop and commercialize novel therapeutics that address unmet medical needs. These achievements demonstrate Titan Pharmaceuticals' commitment to advancing the field of addiction treatment and improving patient outcomes.

Titan Pharmaceuticals Inc is a pharmaceutical company specializing in the development and commercialization of innovative therapeutics for the treatment of chronic diseases. Established in 1992, the company has a rich history of success in the pharmaceutical industry. Titan Pharmaceuticals Inc is known for its expertise in the field of proprietary drug delivery technology, which enables the sustained release of medications. With a strong focus on patient-centric solutions, Titan Pharmaceuticals Inc has made significant contributions to the healthcare sector. The company continually strives to enhance the lives of individuals through its cutting-edge products and commitment to advancing medical science.

The main competitors of Titan Pharmaceuticals Inc in the market include companies like Janssen Pharmaceuticals, Indivior, and Braeburn Pharmaceuticals.

Titan Pharmaceuticals Inc is primarily active in the pharmaceutical industry.

The business model of Titan Pharmaceuticals Inc. focuses on developing and commercializing innovative treatments for chronic diseases through its proprietary drug delivery technologies. The company aims to address various therapeutic areas, including addiction, chronic pain management, and central nervous system disorders. By leveraging its expertise in long-term drug delivery, Titan Pharmaceuticals is committed to providing patients with improved treatment options that enhance compliance, convenience, and efficacy. Through strategic partnerships and collaborations, the company continues to advance its product pipeline and expand its reach in the pharmaceutical market.

P/E odnos Titan Pharmaceuticals iznosi -3,75.

KUV kompanije Titan Pharmaceuticals iznosi 0.

AlleAktien kvalitativni skor za Titan Pharmaceuticals je 2/10.

Prihod trenutno ne može biti izračunat za Titan Pharmaceuticals.

Dobit očekivana Titan Pharmaceuticals je -705.432,06 USD.

Titan Pharmaceuticals Inc is a biopharmaceutical company based in San Francisco, California. The company specializes in the development and marketing of medications for the treatment of serious diseases such as opioid addiction and Parkinson's. The opioid addiction division offers the medication Probuphine, which consists of a combination of buprenorphine and implant technology. This combination allows patients to recover from opioid addiction for up to six months. The implant, which is implanted under the skin, continuously releases buprenorphine, thereby avoiding withdrawal symptoms. The Parkinson's division of the company offers the medication Probuphine, which also consists of implant technology. The medication continuously releases levodopa, which alleviates the symptoms of Parkinson's disease. Titan Pharmaceuticals has acquired exclusive development and marketing rights for Probuphine in the United States. The company has also announced a partnership with JT Pharmaceuticals Inc. to develop and market medications for the treatment of chronic migraines. According to the company, the first clinical studies for this project are already planned for 2021. Titan Pharmaceuticals relies on strong partnerships to market its products worldwide. In 2018, the company signed a strategic agreement with L. Molteni & C. dei F.lli Alitti Società di Esercizio S.p.A to sell Probuphine in Europe. Taking into account rapidly changing market trends and the increasing needs of patients, the company has also developed a digital platform. The platform aims to provide doctors and patients with information about the company's products and support the treatment process. This digital platform is an important part of the marketing concept and helps the company increase its market share. In conclusion, Titan Pharmaceuticals is a rapidly growing company with a wide product portfolio in the field of medical implants. The company relies on strategic partnerships and advanced technologies to market its products worldwide. With a combination of years of experience, technical know-how, and a large number of satisfied patients, Titan Pharmaceuticals is well positioned to continue its success in the future.

Titan Pharmaceuticals isplaćuje dividendu od 0 USD raspoređenu preko isplata u toku godine.

Dividenda za Titan Pharmaceuticals trenutno ne može biti izračunata ili kompanija ne isplaćuje dividendu.

ISIN od Titan Pharmaceuticals je US8883146065.

WKN od Titan Pharmaceuticals je A2QJPT.

Oznaka za praćenje akcija kompanije Titan Pharmaceuticals je TTNP.

U poslednjih 12 meseci, Titan Pharmaceuticals je isplatio dividendu u iznosu od . To odgovara dividendnom prinosu od oko . Za narednih 12 meseci, Titan Pharmaceuticals će verovatno isplatiti dividendu od 0 USD.

Dividendski prinos od Titan Pharmaceuticals trenutno iznosi .

Titan Pharmaceuticals isplaćuje dividende na kvartalnom nivou. One se isplaćuju u mesecima .

Titan Pharmaceuticals je isplaćivao dividendu svake godine u poslednjih 0 godina.

Za narednih 12 meseci očekuju se dividende u iznosu od 0 USD. To odgovara dividendnom prinosu od 0 %.

Titan Pharmaceuticals se svrstava u sektor 'Zdravlje'.

Da biste primili poslednju dividendu od Titan Pharmaceuticals od 30. 12. 2024. u iznosu od 0 USD, morali ste da imate akciju u depou pre Ex-dana 30. 12. 2024..

Isplata poslednje dividende izvršena je 30. 12. 2024..

U godini 2023 kompanija Titan Pharmaceuticals je isplatila 0 USD kao dividende.

Dividende od Titan Pharmaceuticals se isplaćuju u USD.